Efficacy, safety and patient reported outcomes (PROS) in adult patients with atopic dermatitis treated with dupilumab at week-52 in usual clinical practice
Marron, S.E. ; Alcalde-Herrero, V.M. ; García Latasa de de Aranibar, F.J. (Universidad de Zaragoza) ; Moncin-Torres, C.A. ; Fuentelsaz del Barrio, M.V. ; Alvarez-Salafranca, M. (Universidad de Zaragoza) ; Tomas-Aragones, L. (Universidad de Zaragoza)
Resumen: P15
Background: Dupilumab, an anti-interleikin-4-receptor-a monoclonal antibody, is a new treatment for atopic dermatitis in adults.
Objective: To evaluate – at week 52 – patient reported outcomes, satisfaction, efficacy and safety, with dupilumab in adult patients with moderate-to-severe atopic dermatitis refractory to the usual treatments previously performed under conditions of usual clinical practice.
Methods: Twelve patients were enrolled. Patients from our hospital, under routine clinical practice, were treated with subcutaneous dupilumab 300 mg every 2 weeks. The outcomes were evaluated at baseline, week 4, 8, 12, 16, 28 , 40 and week 52. The variables evaluated were: itch, difficulty to sleep, previous stressful life events, severity (SCORAD), anxiety and depression symptoms (HADS), quality of life (DLQI, EQ5D3L), satisfaction, adherence to the treatment, efficacy and safety.
Results: At week 52 significant improvement was observed in severity, itch, difficulty to sleep, anxiety and depression symptoms, and quality of life. Satisfaction with dupilumab compared to previous treatments was significantly higher in all aspects assessed. No significant dupilumab-induced laboratory abnormalities were noted, and adverse events were mild and transient.
Conclusions: Dupilumab used under routine clinical practice for 52 weeks improved atopic dermatitis signs and symptoms, with a good safety profile and patient satisfaction.
Idioma: Inglés
Año: 2019
Publicado en: ACTA DERMATO-VENEREOLOGICA 99, 8 (2019), 751
ISSN: 0001-5555
Originalmente disponible en: Texto completo de la revista
Factor impacto JCR: 4.016 (2019)
Categ. JCR: DERMATOLOGY rank: 7 / 68 = 0.103 (2019) - Q1 - T1
Factor impacto SCIMAGO: 1.01 - Medicine (miscellaneous) (Q1) - Dermatology (Q1)
Tipo y forma: Congress (Published version)
Área (Departamento): Área Psicolog.Evolut.Educac (Dpto. Psicología y Sociología)
Área (Departamento): Área Dermatología (Dpto. Medicina, Psiqu. y Derm.)
Exportado de SIDERAL (2021-01-28-12:42:39)
Visitas y descargas
Background: Dupilumab, an anti-interleikin-4-receptor-a monoclonal antibody, is a new treatment for atopic dermatitis in adults.
Objective: To evaluate – at week 52 – patient reported outcomes, satisfaction, efficacy and safety, with dupilumab in adult patients with moderate-to-severe atopic dermatitis refractory to the usual treatments previously performed under conditions of usual clinical practice.
Methods: Twelve patients were enrolled. Patients from our hospital, under routine clinical practice, were treated with subcutaneous dupilumab 300 mg every 2 weeks. The outcomes were evaluated at baseline, week 4, 8, 12, 16, 28 , 40 and week 52. The variables evaluated were: itch, difficulty to sleep, previous stressful life events, severity (SCORAD), anxiety and depression symptoms (HADS), quality of life (DLQI, EQ5D3L), satisfaction, adherence to the treatment, efficacy and safety.
Results: At week 52 significant improvement was observed in severity, itch, difficulty to sleep, anxiety and depression symptoms, and quality of life. Satisfaction with dupilumab compared to previous treatments was significantly higher in all aspects assessed. No significant dupilumab-induced laboratory abnormalities were noted, and adverse events were mild and transient.
Conclusions: Dupilumab used under routine clinical practice for 52 weeks improved atopic dermatitis signs and symptoms, with a good safety profile and patient satisfaction.
Idioma: Inglés
Año: 2019
Publicado en: ACTA DERMATO-VENEREOLOGICA 99, 8 (2019), 751
ISSN: 0001-5555
Originalmente disponible en: Texto completo de la revista
Factor impacto JCR: 4.016 (2019)
Categ. JCR: DERMATOLOGY rank: 7 / 68 = 0.103 (2019) - Q1 - T1
Factor impacto SCIMAGO: 1.01 - Medicine (miscellaneous) (Q1) - Dermatology (Q1)
Tipo y forma: Congress (Published version)
Área (Departamento): Área Psicolog.Evolut.Educac (Dpto. Psicología y Sociología)
Área (Departamento): Área Dermatología (Dpto. Medicina, Psiqu. y Derm.)
Exportado de SIDERAL (2021-01-28-12:42:39)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
articulos > articulos-por-area > psicologia_evolutiva_y_de_la_educacion
articulos > articulos-por-area > dermatologia
Notice créée le 2021-01-28, modifiée le 2021-01-28